Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
Total Valuation
scPharmaceuticals has a market cap or net worth of $263.83M. The enterprise value is $216.31M.
Market Cap$263.83M
Enterprise Value$216.31M
Share Statistics
scPharmaceuticals has 53,298,298 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,298,298
Owned by Insiders18.21%
Owned by Institutions0.09%
Financial Efficiency
scPharmaceuticals’s return on equity (ROE) is -6.39 and return on invested capital (ROIC) is -69.56%.
Return on Equity (ROE)-6.39
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-69.56%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee224.27K
Profits Per Employee-525.60K
Employee Count162
Asset Turnover0.34
Inventory Turnover0.82
Valuation Ratios
The current PE Ratio of scPharmaceuticals is ―. scPharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value11.83
Price to FCF―
Price to Operating Cash Flow-3.90
PEG Ratio―
Income Statement
In the last 12 months, scPharmaceuticals had revenue of 36.33M and earned -85.15M in profits. Earnings per share was -1.91.
Revenue36.33M
Gross Profit24.97M
Operating Income-64.78M
Pretax Income-85.15M
Net Income-85.15M
EBITDA-77.43M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was -65.86M and capital expenditures -21.00K, giving a free cash flow of -65.88M billion.
Operating Cash Flow-65.86M
Free Cash Flow-65.88M
Free Cash Flow per Share-1.24
Dividends & Yields
scPharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change-10.16%
50-Day Moving Average4.54
200-Day Moving Average3.56
Relative Strength Index (RSI)44.52
Average Volume (3m)346.98K
Important Dates
scPharmaceuticals upcoming earnings date is Nov 5, 2025, TBA (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
scPharmaceuticals as a current ratio of 7.12, with Debt / Equity ratio of -246.05%
Current Ratio7.12
Quick Ratio6.18
Debt to Market Cap0.33
Net Debt to EBITDA0.30
Interest Coverage Ratio-8.56
Taxes
In the past 12 months, scPharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
scPharmaceuticals EV to EBITDA ratio is -1.74, with an EV/FCF ratio of -1.91.
EV to Sales3.71
EV to EBITDA-1.74
EV to Free Cash Flow-1.91
EV to Operating Cash Flow-1.91
Balance Sheet
scPharmaceuticals has $40.81M in cash and marketable securities with $52.45M in debt, giving a net cash position of $11.64M billion.
Cash & Marketable Securities$40.81M
Total Debt$52.45M
Net Cash$11.64M
Net Cash Per Share$0.22
Tangible Book Value Per Share$0.30
Margins
Gross margin is 68.46%, with operating margin of -178.29%, and net profit margin of -234.36%.
Gross Margin68.46%
Operating Margin-178.29%
Pretax Margin-234.36%
Net Profit Margin-234.36%
EBITDA Margin-213.12%
EBIT Margin-213.53%
Analyst Forecast
The average price target for scPharmaceuticals is $13.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.75
Price Target Upside198.91% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast107.79%
EPS Growth Forecast-16.01%